Medicus Pharma to Highlight Rare Disease and AI Strategies at Roth Conference

Event summary

  • Medicus Pharma to present at 38th Annual Roth Conference on March 24, 2026, focusing on Skinject for Gorlin Syndrome and AI-driven drug development.
  • CEO Dr. Raza Bokhari to discuss $2B Skinject and $6B Teverelix market opportunities in fireside chat with Roth Capital Partners.
  • Company targeting Phase 2 de-risking and strategic partnerships for late-stage development and commercialization.
  • Medicus completed enrollment of 90 patients in Phase 2 Skinject study (SKNJCT-003) and received FDA clearance for Phase 2b Teverelix study.
  • Strategic collaborations include Gorlin Syndrome Alliance, Helix Nanotechnologies, and Reliant AI for AI-driven clinical data analytics.

The big picture

Medicus Pharma's participation in the Roth Conference underscores its focus on strategic partnerships and AI-driven drug development. The company's dual-market approach—targeting $2B Skinject and $6B Teverelix opportunities—positions it within the broader trend of biotech firms leveraging technology to accelerate rare disease treatments. The upcoming Phase 2 data and FDA meetings will be critical in determining the company's path to commercialization.

What we're watching

Regulatory Progress
Whether Medicus can secure an end-of-Phase 2 meeting with the FDA in the first half of 2026 for Skinject.
Partnering Strategy
The pace at which Medicus advances licensing or strategic partnerships for its Phase 2 programs.
AI Integration
How Reliant AI collaboration will impact capital-efficient clinical development and patient enrollment forecasting.